Should I Buy OBIO? OBIO 2026 Analysis

Should You Buy Orchestra Biomed Holdings Inc (OBIO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

3.730

1 Day change

-5.09%

52 Week Range

6.160

Analysis Updated At

2026/01/26

Orchestra Biomed Holdings Inc (OBIO) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company has potential in its innovative cardiovascular device offerings and insider buying indicates confidence, the technical indicators are neutral to bearish, financial performance shows declining revenue, and there are no recent positive news catalysts. Analysts have a positive long-term outlook with price targets significantly above the current price, but the lack of immediate strong signals and weak short-term momentum suggest holding rather than buying now.

Technical Analysis

The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 34.146, and moving averages are converging, showing no clear trend. The stock is trading below the pivot level of 4.401, with support at 3.991 and resistance at 4.812.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Insider buying has increased significantly by 730.61% over the last month, showing confidence from insiders. Analysts have set high price targets of $11-$15, indicating long-term potential.

Neutral/Negative Catalysts

Revenue dropped by 12.77% YoY in Q3 2025, and EPS declined by 2.44% YoY. The MACD and RSI suggest weak momentum, and there are no recent news catalysts or significant hedge fund activity.

Financial Performance

In Q3 2025, revenue dropped to $861,000 (-12.77% YoY), net income improved to -$20.83M (up 35.02% YoY), EPS dropped to -0.4 (-2.44% YoY), and gross margin increased slightly to 94.31% (+1.29% YoY).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are positive on OBIO, with Barclays maintaining an Overweight rating and raising the price target to $12, and TD Cowen initiating coverage with a Buy rating and a $15 price target. Analysts highlight the company's innovative cardiovascular device pipeline and partnerships targeting large markets.

4 Analyst Rating

Wall Street analysts forecast OBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OBIO is 14.25 USD with a low forecast of 10 USD and a high forecast of 20 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 3.930

Low

Averages

14.25

High

Current: 3.930

Low

Averages

14.25

High

Barclays

Matt Miksic

maintain

$11 -> $12

AI Analysis

2026-01-09

Reason

Barclays

Matt Miksic

Price Target

$11 -> $12

AI Analysis

2026-01-09

maintain

Reason

Barclays analyst Matt Miksic raised the firm's price target on Orchestra BioMed to $12 from $11 and keeps an Overweight rating on the shares. The firm updated the company's model.

TD Cowen

Joshua Jennings

Buy

initiated

$15

2025-12-10

Reason

TD Cowen

Joshua Jennings

Price Target

$15

2025-12-10

initiated

Buy

Reason

TD Cowen analyst Joshua Jennings initiated coverage of Orchestra BioMed with a Buy rating and $15 price target. Orchestra BioMed is building a differentiated, royalty-based Med Tech model anchored by Atrioventricular Interval Modulation therapy for hypertension and Virtue SAB for arterial atherosclerotic disease, with both programs targeting large, underserved markets, leverage blue-chip partners, and offering scalable, high-margin economics as pivotal data and commercialization milestones approach, the analyst tells investors in a research note. These two assets position Orchestra BioMed at the leading edge of cardiovascular device innovation, the firm argues.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for OBIO

Unlock Now

OBIO Should I Buy

OBIO Should I Buy

Should You Buy Orchestra Biomed Holdings Inc (OBIO) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch